Net revenue of Fresenius Medical Care AG & Co. KGaA (“the Company”) was $8,499 million, up 26% compared to 2005. Adjusted for currency, net revenue rose 25%.

Operating income (EBIT) increased by 40% to $1,318 million. Excluding costs related to the change of accounting principles for stock options (SFAS 123R) and one-time items, the operating income increased by 38% to $1,329 million

For the full year 2006, net income was $537 million, up 18% from 2005.
Excluding costs related to SFAS 123R and one-time items, net income for 2006 increased by 24% to $584 million.

For the tenth consecutive year, shareholders can expect to receive an increased annual dividend. At the Annual General Meeting to be held on May 15, 2007, shareholders will be asked to approve a dividend per ordinary share of €1.41, an increase of 15% (2005: €1.23).

For the full year 2007, the Company expects to achieve revenue of approximately $9.4 billion, an increase of 11%. The net income is expected to be between $675 million and $695 million in 2007. This represents an increase of between 18% and 21% on an adjusted basis to 2006. On a reported basis, the net income would increase by 26% to 29%. The Company expects capital expenditures and spending on acquisitions to be approximately $650 million.

Fresenius AG (WKN 578560, 578563) holds approximately 36% of Fresenius Medical Care AG & Co. KGaA’s capital.

Fresenius Medical Care AG & Co. KGaA,
Represented by Fresenius Medical Care Management AG,
Board of Management,
Bad Homburg v.d.H., February 22, 2007